MPM Bioimpact LLC Reduces Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

MPM Bioimpact LLC lowered its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 24.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,106,851 shares of the company’s stock after selling 358,950 shares during the quarter. MPM Bioimpact LLC’s holdings in Zentalis Pharmaceuticals were worth $3,354,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently modified their holdings of ZNTL. Nuveen Asset Management LLC grew its stake in Zentalis Pharmaceuticals by 35.2% during the 4th quarter. Nuveen Asset Management LLC now owns 641,407 shares of the company’s stock worth $1,943,000 after buying an additional 167,062 shares during the last quarter. Millennium Management LLC grew its stake in shares of Zentalis Pharmaceuticals by 8.1% in the 4th quarter. Millennium Management LLC now owns 957,563 shares of the company’s stock worth $2,901,000 after purchasing an additional 71,477 shares during the last quarter. Integral Health Asset Management LLC acquired a new stake in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $3,182,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of Zentalis Pharmaceuticals in the 4th quarter valued at $703,000. Finally, Graham Capital Management L.P. boosted its holdings in shares of Zentalis Pharmaceuticals by 37.4% in the fourth quarter. Graham Capital Management L.P. now owns 57,946 shares of the company’s stock worth $176,000 after buying an additional 15,760 shares during the period.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other Zentalis Pharmaceuticals news, Director Scott Dunseth Myers bought 21,000 shares of the firm’s stock in a transaction dated Wednesday, April 30th. The stock was purchased at an average cost of $1.40 per share, with a total value of $29,400.00. Following the transaction, the director now directly owns 281,192 shares in the company, valued at $393,668.80. This trade represents a 8.07% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 3.60% of the company’s stock.

Zentalis Pharmaceuticals Stock Down 6.2%

Shares of ZNTL stock opened at $1.21 on Wednesday. Zentalis Pharmaceuticals, Inc. has a twelve month low of $1.01 and a twelve month high of $13.00. The company has a market cap of $87.06 million, a P/E ratio of -0.49 and a beta of 1.81. The business has a fifty day simple moving average of $1.47 and a 200 day simple moving average of $2.36.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its quarterly earnings results on Wednesday, March 26th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.09. The firm had revenue of $26.90 million for the quarter. As a group, equities research analysts anticipate that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research report on Thursday, March 27th. UBS Group decreased their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company cut their price objective on shares of Zentalis Pharmaceuticals from $8.00 to $6.00 and set an “equal weight” rating for the company in a research report on Thursday, January 30th. Finally, Wedbush reiterated a “neutral” rating and issued a $4.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, March 28th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $8.24.

Zentalis Pharmaceuticals Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.